Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTyratech Regulatory News (TYR)

  • There is currently no data for TYR

Establishing Unrestricted Trading Line

19 Jul 2010 07:00

RNS Number : 5028P
TyraTech, Inc.
19 July 2010
 



For Immediate Release

19 July 2010

 

TYRATECH, INC.

("TyraTech" or "the Company")

 

Establishing Unrestricted Trading Line

 

TyraTech, Inc. (AIM: TYR), a leading independent novel pesticide company for human, animal and environmental health, is pleased to announce that the Company has started the process of establishing a second trading facility (AIM: TYRU) to enable certain eligible Common Shares to have US trading restrictions removed. Removal of trading restrictions allows the shares to be:

 

·; transferred to a new unrestricted trading line (AIM: TYRU);

·; settled, by means of Depositary Interests, through the CREST electronic settlement system; and

·; sold in the US if the holders elect.

 

The Company expects that trading on this second, unrestricted line will begin around the end of August 2010.

 

TyraTech currently has a total of 47,193,022 Common Shares admitted to AIM and trading under the symbol TYR in a restricted manner as permitted by Regulation S of the U.S. Securities Act of 1933 (the 'Securities Act').  Common Shares that have been in issue for more than one year and are not held by 'affiliates' generally qualify for characterisation as 'Unrestricted Common Shares' under an exemption provided by Rule 144(k) of the Securities Act. All Unrestricted Common Shares will be eligible for migration to, and trading on, the unrestricted TYRU line once the trading facility is formally in place. All shares not meeting the definition of Unrestricted Common Shares will continue to trade in a restricted manner under the TYR line. There is no difference between the Common Shares trading in the restricted line and those trading in the unrestricted line, but the TYRU line will serve to evidence the absence of restrictions on trading otherwise imposed by the Securities Act that will enable electronic settlement if a holder so desires.

 

The Directors of TyraTech believe that creating a second line to enable its unrestricted Common Shares to trade and settle electronically via the CREST system will make investing in the Company more attractive to many investors and could improve liquidity under the unrestricted trading symbol.

 

In the coming weeks, the Company will announce the date when trading on the TYRU line will commence and the CREST settlement system will be enabled for these shares. The Company has sent letters to eligible shareholders with instructions for migrating their shares to the TYRU line. To participate, holders of eligible shares must deliver their current restricted share certificate to the Company's transfer agent (Computershare - Channel Islands) together with the Letter of Transmittal provided to them by August 13 2010 and will receive an unrestricted certificate in return.

 

Copies of the letter to shareholders and the Letter of Transmittal are available at www.tyratech.com.

 

 

For further information please contact:

TyraTech Inc.

Keith Bigsby, Chief Financial Officer +1 (321) 409 7714

www.tyratech.com

Nomura Code Securities

Richard Potts/Christopher Golden +44 (0)20 7776 1200

www.nomuracode.com

Buchanan Communications

Lisa Baderoon/ Catherine Breen +44 (0) 20 7466 5000

www.buchanan.uk.com

 

About TyraTech

TyraTech was formed in 2004 to develop and commercialise products for the control of invertebrate pests and pathogens using the Company's proprietary technology. TyraTech, which already has products on the market, is positioned for human health, animal health and pesticide market opportunities which total over $32 billion globally. TyraTech's technology provides the Company with a wide variety of product and business opportunities in many markets and geographic regions. The differentiating feature of these products is the potential to have a combined level of potency and safety that other invertebrate control products are unable to offer. TyraTech's platform brings many of the principles of drug discovery and development to the fields of insecticides and parasiticides. By targeting specific chemoreceptors that are found in invertebrates but not in humans and animals, TyraTech can produce products that use natural plant derived compounds targeting these receptors.

 

TyraTech is actively developing selected proprietary active ingredients which can then be used for various products across a wide variety of market segments, either by development partners or by TyraTech itself. TyraTech already has products or partnerships in the areas of professional and horticultural insect control, and for an insect/mosquito repellent. TyraTech also has an innovative partnership with Kraft to use its natural oils to develop functional foods for improving the health of the more than 2 billion people worldwide subject to intestinal parasitic infections.

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCKKADPQBKDQOD
Date   Source Headline
8th Nov 20185:25 pmRNSTyratech
2nd Nov 20185:30 pmRNSTyratech
31st Oct 20183:01 pmRNSResult of Special Meeting, Cancellation from AIM
25th Oct 20187:00 amRNSSpecial Meeting and Acquisition Update
18th Oct 20183:00 pmRNSNominee accounts
9th Oct 20182:23 pmRNSPosting of Proxy Statement and Timetable Update
5th Oct 201810:05 amRNSUpdate
28th Sep 20188:50 amRNSInterim Results
28th Sep 20187:00 amRNSConditional Merger Agreement Signed with AMVAC
23rd May 20187:00 amRNSFinal Results
9th May 20187:00 amRNSProgress in 2018 on products and milestones
3rd May 20187:00 amRNSChange of Adviser
24th Jan 20185:44 pmRNSHolding(s) in Company
18th Jan 20187:00 amRNSHolding(s) in Company
15th Jan 20187:00 amRNSResult of Tender Offer
11th Jan 20181:08 pmRNSTR-1
9th Jan 20185:01 pmRNSTR-1
5th Jan 20187:00 amRNSResult of Tender Offer
28th Dec 20177:00 amRNSResult of Special Meeting
4th Dec 20177:00 amRNSTender Offer to Shareholders and Notice of Meeting
12th Sep 20177:00 amRNSInterim Results for Six Months Ended 30 June 2017
24th Aug 20177:00 amRNSCOMPANY UPDATE AND DATE OF INTERIM RESULTS
4th Jul 20172:29 pmRNSJoint Development and License Agreement
29th Jun 20177:00 amRNSResult of AGM
7th Jun 20177:00 amRNSTYR TR-1: Notification of major interest in shares
9th May 20177:00 amRNSResults for the Year Ended 31 December 2016
28th Apr 20173:24 pmRNSFurther re Notice of Final Results
22nd Mar 20178:57 amRNSTR-1: Notification of major interest in shares
9th Feb 20177:00 amRNSPre-close Trading Update
19th Sep 20163:59 pmRNSDirector/PDMR Shareholding
15th Sep 20161:18 pmRNSDirectors' Dealings
13th Sep 20167:00 amRNSInterim Results for Six Months Ended 30 June 2016
28th Jul 20167:00 amRNSPre Close Trading Update
8th Jun 20163:22 pmRNSResult of AGM and Board Change
22nd Apr 20161:57 pmRNSDirectors' Dealings
15th Apr 201612:03 pmRNSAward of Share Options
15th Apr 201611:57 amRNSDirectors' Dealings
14th Apr 20167:00 amRNSDirectors' Dealings
11th Apr 20167:00 amRNSAppointment of José Barella as Chairman
4th Apr 20167:00 amRNSNotice of Preliminary Results
3rd Feb 201612:31 pmRNSHolding(s) in Company
1st Feb 20161:08 pmRNSDirector's Dealings
1st Feb 20167:00 amRNSPre-close Trading Update
20th Jan 20167:00 amRNSAppointment of Erica H. Boisvert as CFO
13th Jan 20167:00 amRNSNew Product Range Launch & Distribution Agreement
17th Dec 20154:01 pmRNSTR-1: Notification of Major Interest in Shares
4th Dec 201511:00 amRNSTR-1: Notification of major interest in shares
26th Nov 201512:51 pmRNSTR-1: Notification of Major Interest in Shares
16th Nov 20155:01 pmRNSResult of Special Meeting & Director Shareholdings
4th Nov 20157:00 amRNSPlacing and Subscription to raise £3.16m

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.